Smallpox Vaccination Plan Is 'Kaput'--Or Is It?

Frontlines | Smallpox Vaccination Plan Is 'Kaput'--Or Is It? On Dec. 14, 2002, the Bush Administration announced its plan to vaccinate within a 30-day period about 400,000 to 500,000 healthcare workers and "other critical personnel" against smallpox.1 That plan fizzled amid concerns about possible serious adverse reactions and confusion about who could be vaccinated safely.2 By Oct. 10, the Centers for Disease Control and Prevention (CDC) Web site indicated that only 38,542 people are v

Written byMyrna Watanabe
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

On Dec. 14, 2002, the Bush Administration announced its plan to vaccinate within a 30-day period about 400,000 to 500,000 healthcare workers and "other critical personnel" against smallpox.1 That plan fizzled amid concerns about possible serious adverse reactions and confusion about who could be vaccinated safely.2

By Oct. 10, the Centers for Disease Control and Prevention (CDC) Web site indicated that only 38,542 people are vaccinated nationwide, but that 291,400 vaccine doses had been shipped to the states. About a week later, USA Today reported that a CDC official said the plan "has stopped."3 Not so, wrote CDC Director Julie Gerberding in a letter published in the paper's Oct. 23 issue. It "continues," she wrote, but now, "the vaccination program is only one element of smallpox preparedness."

CDC spokesman Tom Skinner elaborated, saying that the agency is educating clinicians to diagnose the disease, training public health officials and epidemiologists to ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies